ECM
KNSA icon

Endurant Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Endurant Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-244,125
Closed -$2.87M – 77
2021
Q4 		$2.87M Buy
+244,125
New +$3M 0.69% 33
2021
Q1 		– Sell
-133,648
Closed -$2.36M – 65
2020
Q4 		$2.36M Buy
133,648
+16,168
+14% +$284K 0.85% 37
2020
Q3 		$1.8M Buy
+117,480
New +$2.21M 0.53% 46

Other funds holding KNSA

PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Endurant Capital Management's KNSA Position: Q1 2022 in Review

Endurant Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2022, closing a stake of 244,125 shares — an estimated $2.87M sold.

Endurant Capital Management first reported a position in KNSA in Q3 2020 and held it in 3 quarters. The position peaked at $2.87M in Q4 2021. 96 funds tracked by Wall St. Rank hold KNSA as of Q1 2022.

  • Endurant Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Endurant Capital Management sold 244,125 Kiniksa Pharmaceuticals shares in Q1 2022, an estimated $2.87M.
  • Endurant Capital Management first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Endurant Capital Management's Kiniksa Pharmaceuticals position peaked at $2.87M in Q4 2021.
  • 96 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2022.

Based on Endurant Capital Management's 13F filing for Q1 2022, filed 16 May 2022.